NCT04770467View on ClinicalTrials.gov

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
COVID-19
Interventions
DRUG

BRII-196 and BRII-198

BRII-196 and BRII-198 given by intravenous administration

DRUG

Placebo

Placebo given by intravenous administration

Trial Locations (1)

Unknown

Investigative Site 1, Hong Kong

Sponsors
All Listed Sponsors
lead

Brii Biosciences, Inc.

INDUSTRY